Phase I, open-label study in 15 healthy adult subjects receive 6 mg of auranofin orally once
every 24 hours for 7days. Blood samples will be taken for 17 weeks following the last dose of
auranofin for determination of terminal phase pharmacokinetic parameters. Stool samples will
also be obtained for the measurement of gold.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)